Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, mutation profiles of BRAF wild-type craniopharyngiomas and ameloblastomas share mutations of FGFR genes and have additional mutations with potential for targeted therapy.
|
29546640 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In total, 14-50% of adult-onset craniopharyngioma are papillary; the majority with a mutation in exon 3 of BRAF and may respond to BRAF inhibitors and mitogen-activated protein kinase inhibitors.
|
27258775 |
2016 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To establish preoperative prediction criteria to identify patients with a BRAF mutant craniopharyngioma.
|
30481321 |
2019 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutations were solely found in the papCP subgroup and were not detectable in adaCP samples.
|
26927026 |
2016 |
Craniopharyngioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As these targetable mutations warrant prospective research, the authors will be conducting a national National Cancer Institute-sponsored multicenter clinical trial to investigate BRAF/MEK inhibition in the treatment of craniopharyngioma.
|
27903124 |
2016 |
Craniopharyngioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A thorough analysis of the alterations of β-catenin/CTNNB1 and BRAF genes investigated in 1123 CP cases included in 27 studies, showed that, on average, CTNNB1 mutations were present in two-thirds of adamantinomatous CPs and BRAF mutations in 90% of papillary CPs.
|
29700680 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RESULTS Eight of the 52 patients had BRAF-mutated craniopharyngiomas, and the remaining 44 had BRAF WT tumors.
|
28984520 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papillary craniopharyngiomas are defined by BRAF <sup>V600E</sup> mutations while β-catenin alterations characterize adamantinomatous craniopharyngiomas.
|
29396598 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily).
|
26498373 |
2016 |
Craniopharyngioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The advent of targeted therapy of the BRAF/MEK pathway is associated with new therapeutic opportunities for patients with craniopharyngiomas.
|
29952427 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent insight in molecular pathogenesis of CP opens new perspectives on targeted therapy in papillary CP harboring BRAF-V600E mutations.
|
31678973 |
2019 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutant papillary tumors represent a clearly distinct clinical-pathological entity of craniopharyngiomas.
|
30187175 |
2018 |
Craniopharyngioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although established approaches along with new surgical and radiotherapeutic approaches remain the main treatment modalities, recent evidence has provided insight into their molecular pathogenesis involving, other than chemotherapy, treatments with targeted agents as in gliomas and craniopharyngiomas bearing BRAF mutations.
|
30779850 |
2019 |
Craniopharyngioma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
Craniopharyngioma
|
0.600 |
SomaticCausalMutation
|
disease |
ORPHANET |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |